Separate names with a comma.
Discussion in 'Marijuana News' started by ocsurfer, Dec 1, 2011.
Bummer, but par for the course...
so they dismiss it because it is a schedule one drug...
and the dea refuses to reschedule it...
is anyone suing the dea to reclassify it?
Not suing per se, but appealing the denial of the last petition:
ASA : Patient Advocates Appeal Federal Decision to Deny Medical Marijuana to Millions of Americans
The Supreme Court dismissed this based on a Schedule I ruling? Only because pharma can't control marijuana. When pharma sees a Schedule I drug that they can control, they don't hesitate to cash in on it, and the Supreme Court turns a blind eye.
The Supreme Court should show a bit more consistency in how it interprets drug scheduling:
GHB: Gamma-Hydroxybutyric Acid / Sodium Oxybate. DEA Schedule #2010: Schedule 1.
Gamma-Hydroxybutyric acid - Wikipedia, the free encyclopedia
Quote: GHB as the sodium salt, known as sodium oxybate, is sold by Jazz Pharmaceuticals under the name Xyrem
Xyrem: Sodium Oxybate. Also DEA Schedule #2010, Schedule 3.
Xyrem - Wikipedia, the free encyclopedia
Quote: In the US, Xyrem is classified as a Schedule III controlled substance for medicinal use under the Controlled Substances Act, with illicit use subject to Schedule I penalties. Examples of other schedule III products in the US include vicodin, tylenol with codeine, and testosterone. In Canada and the European Union (EU), it is classified as a Schedule III and a Schedule IV controlled substance, respectively.
Not trying to be nit-picky but the Supreme Court of the U.S. was not involved in this lawsuit. Also I don't believe that the Supreme Court has any role in determining the schedule of controlled substances.
I didn't say "determine". I said "interpret". I think there is sufficient precedent for a more favorable interpretation of marijuana's current schedule I status for use as medicine. Just sayin.